A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

Inclusion Criteria

1. Otherwise healthy male or female infant who is between 0 and 12 months of age.

2. Presents to clinic with a URI characterized by the presence of rhinorrhea and cough
for 7 or fewer days' duration.

3. Patient is an appropriate candidate, in the judgment of the investigator, to
participate in the study.

4. Parents/caregivers provide an answer of at least "somewhat" (3 points on a 7-point
Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough
frequency, effect on child's sleep, and effect on parental/caregiver sleep based on
the previous night's symptoms (see Section 11.0).

5. Parent/legal authorized representative provides written informed consent for child to
participate in study.

6. Parent/caregiver who is willing and able to comply with study requirements.

Exclusion Criteria

1. Signs or symptoms of a more treatable disease (eg, asthma, pneumonia,
laryngotrachebronchitis, sinusitis, allergic rhinitis).

2. Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV).

3. History of reactive airways disease, asthma, or chronic lung disease.

4. Use of any medication to treat cough within 6 hours of bedtime on the evening prior
to or on the day of enrollment. (Use of analgesic medications such as acetaminophen
or ibuprofen is not exclusionary.)

5. Presence of any significant disease including immunodeficiency, hepatic, renal,
cardiovascular, or hematologic disease or any other health condition that, in the
opinion of the investigator, would preclude participation in the study.